Estimation of clinical trial success rates and related parameters

Biostatistics - Tập 20 Số 2 - Trang 273-286 - 2019
Chi Heem Wong1, Kien Wei Siah1, Andrew W. Lo2
1MIT Computer Science and Artificial Intelligence Laboratory & Department of Electrical Engineering and Computer Science, Cambridge, MA 02139, USA and MIT Sloan School of Management and Laboratory for Financial Engineering, Cambridge, MA 02142, USA
2MIT Computer Science and Artificial Intelligence Laboratory & Department of Electrical Engineering and Computer Science, Cambridge, MA 02139, USA, MIT Sloan School of Management and Laboratory for Financial Engineering, Cambridge, MA 02142, USA, and AlphaSimplex Group, LLC, Cambridge, MA 02142, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Abrantes-Metz, 2005, Pharmaceutical development phases: a duration analysis., Journal of Pharmaceutical Finance, Economics and Policy, 14, 19, 10.1300/J371v14n04_03

Danzon, 2005, Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances., Journal of Health Economics, 24, 317, 10.1016/j.jhealeco.2004.09.006

DiMasi, 2010, Trends in risks associated with new drug development: success rates for investigational drugs., Clinical Pharmacology and Therapeutics, 87, 272, 10.1038/clpt.2009.295

Hay, 2014, Clinical development success rates for investigational drugs., Nature Biotechnology, 32, 40, 10.1038/nbt.2786

Malec, 2014, Nonparametric kernel density estimation near the boundary., Computational Statistics & Data Analysis, 72, 57, 10.1016/j.csda.2013.10.023

Martin, 2017, Trial watch: clinical trial cycle times continue to increase despite industry efforts., Nature Reviews Drug Discovery, 16, 157, 10.1038/nrd.2017.21

Root, 2014, Biogen Idec Moves Aggressively, Advances Alzheimer Drug into Phase 3.

Smietana, 2016, Trends in clinical success rates., Nature Reviews Drug Discovery, 15, 379, 10.1038/nrd.2016.85

Thomas, 2016, Clinical Development Success Rates 2006–2015.

2016, Novel Drugs Summary 2015